Clinical trials: Lymphatic Disorders
Eosinophilic Esophagitis
CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry
The purpose of this study is to validate the online cohort of EGID patients enrolled in the RDCRN CEGIR CR. In order to achieve this objective, the investigators will determine the agreement between self-reported EGID information…
- Trial name
- NCT03382678
- Where
- 2 sites in United States
- Volunteers
- 187 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Relapsed AML, T(8;21)
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
In this multi-center, open-label, no control,prospective clinical trial, a total of 30 relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation patients will be enrolled.
- Conditions
- Relapsed AML, T(8;21), C-KIT Mutation
- Trial name
- NCT03560908
- Testing
- Dasatinib
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphatic Filariasis
Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali
Lymphatic filariasis is a public health problem in Mali. The existing data are not up to date and most of them are more than 15 years old.
- Trial name
- NCT02784743
- Testing
- ''albendazole'' and ''ivermectin''
- Volunteers
- 1,139 people, healthy volunteers welcome
- Sponsor
- Centre d'Appui à la lutte contre la Maladie
Hemophilia B
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B.
- Trial name
- BEYOND-9 (NCT06379789)
- Testing
- REGV131, LNP1265
- Where
- 52 sites in United States, Australia and 7 more
- Volunteers
- 130 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma and Plasma Cell Neoplasm
Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma
RATIONALE: Biological therapies, such as antithymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00378768
- Testing
- anti-thymocyte globulin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab
This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy.
- Trial name
- NCT01311232
- Where
- 4 sites in China, Malaysia and 2 more
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Acute Lymphoblastic Leukemia, Pediatric
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
This study aims to compare the effects of two different conditioning regimens on patients with acute lymphoblastic leukemia (ALL) undergoing matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT): Total Body…
- Trial name
- NCT06564493
- Testing
- TBI, TMLI, Cyclophosphamide
- Where
- China
- Volunteers
- 170 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Hematologic Malignancy
Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study
A study of pharmacokinetics of daily intravenous busulfan
- Trial name
- NCT00156858
- Testing
- intravenous busulfan
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Alberta Health services
Moderate or Severe Hypoxic-ischemic Encephalopathy in Newborns
A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
This study will test the safety and efficacy of an infusion of a baby's own (autologous) umbilical cord blood as compared with placebo in babies born with history and signs of hypoxic-ischemic brain injury.
- Trial name
- (HIE) (NCT02612155)
- Testing
- Infusion of autologous cord blood
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Michael Cotten
Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Multi-center observational study to evaluate the histopathology and transcriptome of cutaneous lesions in patients with several different types of vasculitis.
- Conditions
- Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), IgA Vasculitis
- Trial name
- CUTIS (NCT03004326)
- Where
- 10 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Peter Merkel
Blood Disease
The Combination of IVIG, Dexamethasone and a Megadose of PBSCs for Decreasing DSAs
Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor.
- Trial name
- NCT06471478
- Testing
- intravenous immunoglobulin, dexamethasone and a megadose of peripheral-blood stem cell transfusion
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Hematology department of the 920th hospital
Leukemia, Acute, MDS
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
This study is to explore the efficacy and safety of introduction of chidamide in PTCy based GVHD prophylaxis in patients undergoing allogeneic PBSCT.
- Trial name
- NCT03336632
- Testing
- Chidamide, Cyclophosphamide, cyclosporine A
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Sichuan University
Hemophilia A
PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
An open-label, single-arm, post- authorization pragmatic clinical trial on the safety and efficacy of Xyntha (Moroctocog-alfa (AF-CC), Recombinant FVIII) in subjects with hemophilia A in usual care settings in China for…
- Trial name
- NCT02492984
- Testing
- Intravenous infusions of Xyntha
- Where
- 15 sites in China
- Volunteers
- 85 people
- Sponsor
- Pfizer
Acute Lymphoblastic Leukemia
Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL
Asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia (ALL). Clinical hypersensitivity reactions and PEG-asparaginase inactivation is common (12-13% of the patients on the NOPHO (Nordic Society for…
- Trial name
- NCT06195735
- Where
- Denmark
- Volunteers
- 649 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Immune Thrombocytopenia
The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia
This is a multisite, double-blind, randomized, placebo-controlled, and parallel study designed to evaluate the clinical efficacy and safety of Huaiqihuang granule for treatment to children with chronic primary immune…
- Trial name
- ITP (NCT03201848)
- Testing
- Huaiqihuang Granule
- Where
- 14 sites in China
- Volunteers
- 216 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Trial name
- NCT00079404
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Infantile Hemangioma, Capillary Hemangioma
A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China
Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear.
- Conditions
- Infantile Hemangioma, Capillary Hemangioma, Capillary Hemangiomas, Hemangioma, Capillary Infantile
- Trial name
- IH (NCT03173352)
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Sarcoidosis
Study of Eye Tissue for Sarcoidosis
The purpose of this study is to develop a relatively simple, accurate method of diagnosing sarcoidosis. Sarcoidosis is a disease in which granulomas (nodules of inflamed tissue) develop in various organs, such as the lungs…
- Trial name
- NCT00001278
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Eye Institute (NEI)
Hemophilia A
Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII
Patients with severe hemophilia and inhibitors can be treated effectively by Activated Prothrombin Complex Concentrates (APCC, eg. FEIBA) or High dose recombinant factor VIIa (rFVIIa).
- Trial name
- NCT00284193
- Testing
- rFVIIa-FEIBA therapy for hemophilia A inhibitors, FEIBA- Activated Prothrombin Complexes
- Volunteers
- 5 people
- Sponsor
- Sheba Medical Center
Anemia, Traumatic Brain Injury
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
The purpose of this study is to determine the effect of early administration of recombinant human erythropoietin on long-term neurological outcome after severe traumatic brain injury.
- Trial name
- NCT00313716
- Testing
- recombinant human erythropoietin, rhEpo
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Claudia Sue Robertson
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.